Progress on application of PD⁃1／PD⁃L1 monoclonal antibodies in oncotherapy
- VernacularTitle:PD⁃1／PD⁃L1类单抗药物在肿瘤治疗中的应用进展
- Author:
WANG Si⁃yuan
1
;
LU Hui
;
YANG Chun
Author Information
- Publication Type:Journal Article
- Keywords: Programmed death receptor⁃1／programmed death ⁃ ligand 1（PD⁃1／PD⁃L1）；Monoclonal antibodies；Tumor； Immunotherapy
- From: Chinese Journal of Biologicals 2023;36(1):105-111+118
- CountryChina
- Language:Chinese
- Abstract: Abstract：Programmed death receptor⁃ 1（PD⁃1）belongs to the family of immunoglobulin B7⁃CD28，which plays an important role in regulating immune response in human body. Since the first PD⁃1／PD⁃ligand 1（PD⁃L1）monoclonal antibody was approved for marketing in China in 2018，the value of PD⁃1／PD⁃L1 immunotherapy in oncotherapy has attracted wide attention. Based on the introduction of the action mechanism of PD⁃1／PD⁃L1 mAbs，this paper reviews the application progress of 8 on ⁃ market PD ⁃ 1／PD ⁃ L1 mAbs in China in oncotherapy from the perspectives of approved indications，clinical trials，usage and dosage，and adverse reactions，in order to provide reference for the rational appli⁃ cation of PD⁃1／PD⁃L1 monoclonal antibodies in clinic.
- Full text:PD⁃1／PD⁃L1类单抗药物在肿瘤治疗中的应用进展.pdf
